Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in active ulcerative colitis
NCT03100864Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Primary completion
- Aug 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in ulcerative colitis (UC), sponsored by Boehringer Ingelheim. Primary endpoint: Total Number of Deregulated Genes Comparing Baseline to Post Treatment at 12 weeks. Started May 2017; status: completed.
02
Drugs
spesolimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03100864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100864.